Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002196
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of CI-1012 in HIV-Infected Patients
Sponsor:
Parke-Davis
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Multiple Oral Rising-Dose Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers
Status:
COMPLETED
Status Verified Date:
1998-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease This study also examines how the body handles CI-1012
Detailed Description:
Patients receive 2 weeks of oral CI-1012 therapy in this open-label study with 8 patients entered at each dose level studied
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1012-005 | None | None | None |